Changmei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Changmei Zhang has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Sheng Tai
Department of Hepatic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China
4 shared publications Feng Wang
Department of Children’s and Adolescent Health, Public Health College, Harbin Medical University, Harbin 150086, China
3 shared publicationsHaiyan Zhu
Department of Children's and Adolescent Health, Public Health College, Harbin Medical University, Harbin 150086, China; Heilongjiang Province Key Laboratory of Child Development and Genetic Research, Harbin Medical University, Harbin 150086, China
3 shared publicationsQiong Sun
Department of Children's and Adolescent Health, Public Health College, Harbin Medical University, Harbin 150086, China; Heilongjiang Province Key Laboratory of Child Development and Genetic Research, Harbin Medical University, Harbin 150086, China
3 shared publicationsZehui Liu
Department of Children’s and Adolescent Health, Public Health College, Harbin Medical University, Harbin 150086, China
3 shared publicationsZhong Chen
Department of Pharmaceutics, Daqing Campus of Harbin Medical University, Daqing, China
3 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Elsevier in Neurobiology of Disease
- Vol. 226, 107470
Hippocampal APOE/S1P axis regulates synaptic and behavioral deficits in a mouse model of autism
- 4 June 2026
- Published by Elsevier in Neurobiology of Disease
- Vol. 226, 107470
Open AccessHippocampal APOE/S1P axis regulates synaptic and behavioral deficits in a mouse model of autism
- Open Access
- 25 May 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (6) , 649
Camptothecin Nanowires Induce the cGAS-STING Pathway to Remold Tumor-Associated Macrophages for Antitumor Immunity
Background/Objectives: This study aimed to develop a novel tumor-associated macrophage (TAM)-targeting nanoplatform to improve the solubility and bioavailability of camptothecin (CPT) and achieve active targeted drug delivery for enhanced anti-tumor immunotherapy. Methods: We constructed a sialic acid-disulfide bond-camptothecin (SA-SS-CPT) nanowire system. Sialic acid was used as a targeting ligand to specifically recognize the overexpressed Siglec-E receptor on TAMs. Upon cellular internalization, the disulfide bond was designed to respond to intracellular glutathione (GSH), enabling controlled drug release. Results: The SA-SS-CPT nanowires significantly improved CPT solubility and enabled targeted delivery to TAMs. Following GSH-responsive cleavage and CPT release, the nanowires induced DNA damage in TAMs, activating the cGAS-STING signaling pathway. This promoted TAM polarization toward the M1 phenotype, enhanced pro-inflammatory and anti-tumor immune responses, and inhibited tumor immune escape. Furthermore, SA-SS-CPT synergistically improved the efficacy of PD-L1 blockade immunotherapy, remodeling the tumor immune microenvironment. Conclusions: The SA-SS-CPT nanoplatform effectively targets TAMs, repolarizes them to an anti-tumor M1 phenotype, and activates the cGAS-STING pathway. It shows strong potential for overcoming tumor immune escape and synergizing with PD-L1 checkpoint blockade to achieve significant tumor clearance.
- 25 May 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (6) , 649
Open AccessCamptothecin Nanowires Induce the cGAS-STING Pathway to Remold Tumor-Associated Macrophages for Antitumor Immunity
Background/Objectives: This study aimed to develop a novel tumor-associated macrophage (TAM)-targeting nanoplatform to improve the solubility and bioavailability of camptothecin (CPT) and achieve active targeted drug delivery for enhanced anti-tumor immunotherapy. Methods: We constructed a sialic acid-disulfide bond-camptothecin (SA-SS-CPT) nanowire system. Sialic acid was used as a targeting ligand to specifically recognize the overexpressed Siglec-E receptor on TAMs. Upon cellular internalization, the disulfide bond was designed to respond to intracellular glutathione (GSH), enabling controlled drug release. Results: The SA-SS-CPT nanowires significantly improved CPT solubility and enabled targeted delivery to TAMs. Following GSH-responsive cleavage and CPT release, the nanowires induced DNA damage in TAMs, activating the cGAS-STING signaling pathway. This promoted TAM polarization toward the M1 phenotype, enhanced pro-inflammatory and anti-tumor immune responses, and inhibited tumor immune escape. Furthermore, SA-SS-CPT synergistically improved the efficacy of PD-L1 blockade immunotherapy, remodeling the tumor immune microenvironment. Conclusions: The SA-SS-CPT nanoplatform effectively targets TAMs, repolarizes them to an anti-tumor M1 phenotype, and activates the cGAS-STING pathway. It shows strong potential for overcoming tumor immune escape and synergizing with PD-L1 checkpoint blockade to achieve significant tumor clearance.
- Open Access
- 11 March 2026
- Published by MDPI AG in Preprints.org
Camptothecin Nanowires Remold Tumor-Associated Macrophages Polarization Through the cGAS-STING Signaling-Mediated Antitumor Immunity
This study successfully developed a novel tumor-associated macrophages (TAMs)-targeting nanoplatform-sialic acid-disulfide bond-camptothecin (SA-SS-CPT) nanowires. This system significantly improved the solubility and bioavailability of camptothecin (CPT) and achieved active targeted drug delivery by utilizing sialic acid as a targeting ligand to specifically recognize the highly expressed Siglec-E receptor on TAMs. Upon internalization into TAMs, the disulfide bond in the SA-SS-CPT nanowires was cleaved in response to intracellular glutathione (GSH), leading to the controlled re-lease of CPT. SA-SS-CPT induced DNA damage in TAMs, thereby activating the cGAS-STING signaling pathway, promoting the polarization of TAMs toward the M1 phenotype, enhancing pro-inflammatory and anti-tumor immune responses, and effec-tively inhibiting tumor immune escape. Furthermore, the SA-SS-CPT nanowires syner-gistically enhanced the efficacy of PD-L1 blockade immunotherapy, collectively remod-eling the tumor immune microenvironment and ultimately facilitating significant tumor clearance.
- 11 March 2026
- Published by MDPI AG in Preprints.org
Open AccessCamptothecin Nanowires Remold Tumor-Associated Macrophages Polarization Through the cGAS-STING Signaling-Mediated Antitumor Immunity
This study successfully developed a novel tumor-associated macrophages (TAMs)-targeting nanoplatform-sialic acid-disulfide bond-camptothecin (SA-SS-CPT) nanowires. This system significantly improved the solubility and bioavailability of camptothecin (CPT) and achieved active targeted drug delivery by utilizing sialic acid as a targeting ligand to specifically recognize the highly expressed Siglec-E receptor on TAMs. Upon internalization into TAMs, the disulfide bond in the SA-SS-CPT nanowires was cleaved in response to intracellular glutathione (GSH), leading to the controlled re-lease of CPT. SA-SS-CPT induced DNA damage in TAMs, thereby activating the cGAS-STING signaling pathway, promoting the polarization of TAMs toward the M1 phenotype, enhancing pro-inflammatory and anti-tumor immune responses, and effec-tively inhibiting tumor immune escape. Furthermore, the SA-SS-CPT nanowires syner-gistically enhanced the efficacy of PD-L1 blockade immunotherapy, collectively remod-eling the tumor immune microenvironment and ultimately facilitating significant tumor clearance.
- Open Access
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
E-Selectin-Targeted Nanomicelles via Sialic Acid Conjugation for Anti-Inflammatory Efficacy and Alleviating the Progression of Metabolic-Associated Steatotic Liver Disease
Background: Metabolic-associated steatotic liver disease (MASLD), including metabolic dysfunction-associated steatohepatitis (MASH), is a growing health concern characterized by liver inflammation, fibrosis, and endothelial dysfunction. Targeted therapies are essential to address these issues and improve treatment outcomes. Methods: A sialic acid (SA)-modified nanomicelle system (SA-PEG-ALA) was developed to target liver sinusoidal endothelial cells (LSECs) via the E-selectin (SELE). Molecular docking and surface plasmon resonance (SPR) were used to confirm the binding interaction between SA and SELE. In vitro assays using LSECs and steatotic hepatocytes were conducted to evaluate the cellular uptake and therapeutic efficacy of SA-PEG-ALA. In vivo studies using an HFHC-induced MASH mouse model were carried out to evaluate the distribution and therapeutic outcomes of SA-PEG-ALA. Additionally, RNA sequencing was performed to explore the molecular mechanisms underlying its effects. Results: Molecular docking and SPR analyses confirmed that SA effectively binds to SELE, facilitating the targeted delivery of ALA to LSECs. In vitro, SA-PEG-ALA showed substantially higher uptake in LSECs compared to other formulations. In vivo, SA-PEG-ALA demonstrated superior targeting of the liver and showed enhanced therapeutic effects compared to PEG-ALA, significantly alleviating steatosis, liver inflammation, and fibrosis in the MASH model. Mechanistically, SA-PEG-ALA interacted with HSP70, enhancing its stability and promoting the binding of HSP70 to IκBα, which contributed to inhibition of NF-κB signaling pathway. Conclusion: SA-PEG-ALA offers a promising targeted therapeutic strategy for MASLD, with improved liver targeting, anti-inflammatory, and antifibrotic effects, highlighting its potential for treating MASLD.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
Open AccessE-Selectin-Targeted Nanomicelles via Sialic Acid Conjugation for Anti-Inflammatory Efficacy and Alleviating the Progression of Metabolic-Associated Steatotic Liver Disease
Background: Metabolic-associated steatotic liver disease (MASLD), including metabolic dysfunction-associated steatohepatitis (MASH), is a growing health concern characterized by liver inflammation, fibrosis, and endothelial dysfunction. Targeted therapies are essential to address these issues and improve treatment outcomes. Methods: A sialic acid (SA)-modified nanomicelle system (SA-PEG-ALA) was developed to target liver sinusoidal endothelial cells (LSECs) via the E-selectin (SELE). Molecular docking and surface plasmon resonance (SPR) were used to confirm the binding interaction between SA and SELE. In vitro assays using LSECs and steatotic hepatocytes were conducted to evaluate the cellular uptake and therapeutic efficacy of SA-PEG-ALA. In vivo studies using an HFHC-induced MASH mouse model were carried out to evaluate the distribution and therapeutic outcomes of SA-PEG-ALA. Additionally, RNA sequencing was performed to explore the molecular mechanisms underlying its effects. Results: Molecular docking and SPR analyses confirmed that SA effectively binds to SELE, facilitating the targeted delivery of ALA to LSECs. In vitro, SA-PEG-ALA showed substantially higher uptake in LSECs compared to other formulations. In vivo, SA-PEG-ALA demonstrated superior targeting of the liver and showed enhanced therapeutic effects compared to PEG-ALA, significantly alleviating steatosis, liver inflammation, and fibrosis in the MASH model. Mechanistically, SA-PEG-ALA interacted with HSP70, enhancing its stability and promoting the binding of HSP70 to IκBα, which contributed to inhibition of NF-κB signaling pathway. Conclusion: SA-PEG-ALA offers a promising targeted therapeutic strategy for MASLD, with improved liver targeting, anti-inflammatory, and antifibrotic effects, highlighting its potential for treating MASLD.
- 6 August 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (9) , 5443-5457
Dihydroquercetin Nanomicelles Mitigate Hippocampal Apoptosis and Alleviate Autism-Like Behaviors in ASD Rats via the IKK/IKB/NF-κB Signaling Pathway
Dihydroquercetin (DHQ), a compound with neuroprotective effects, has shown its potential in a variety of nervous system diseases. However, its mechanism of action in autism spectrum disorder (ASD) remains to be further explored. Due to its poor solubility, the clinical application of DHQ is restricted. In this study, we aimed to improve the solubility of DHQ by constructing a novel nanodrug delivery system. We utilized the amphiphilic block copolymer MANNOSE-PEG2000-DSPE to encapsulate DHQ, and the resulting formulation was abbreviated as MAN@DHQ. The ASD rats were treated with MAN@DHQ for 7 days. The results of in vivo experiments confirmed that MAN@DHQ could effectively alleviate autism-like behaviors of ASD rats. Western blot results demonstrated that MAN@DHQ mitigate hippocampal apoptosis and ameliorated neuronal damage in the hippocampus of ASD rats via the IKK/IKB/NF-κB signaling pathway. The therapeutic potential of MAN@DHQ in ASD treatment represents a paradigm-shifting advancement in autism pharmacotherapy and offers promise for clinical interventions for ASD patients.
- 6 August 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (9) , 5443-5457
Dihydroquercetin Nanomicelles Mitigate Hippocampal Apoptosis and Alleviate Autism-Like Behaviors in ASD Rats via the IKK/IKB/NF-κB Signaling Pathway
Dihydroquercetin (DHQ), a compound with neuroprotective effects, has shown its potential in a variety of nervous system diseases. However, its mechanism of action in autism spectrum disorder (ASD) remains to be further explored. Due to its poor solubility, the clinical application of DHQ is restricted. In this study, we aimed to improve the solubility of DHQ by constructing a novel nanodrug delivery system. We utilized the amphiphilic block copolymer MANNOSE-PEG2000-DSPE to encapsulate DHQ, and the resulting formulation was abbreviated as MAN@DHQ. The ASD rats were treated with MAN@DHQ for 7 days. The results of in vivo experiments confirmed that MAN@DHQ could effectively alleviate autism-like behaviors of ASD rats. Western blot results demonstrated that MAN@DHQ mitigate hippocampal apoptosis and ameliorated neuronal damage in the hippocampus of ASD rats via the IKK/IKB/NF-κB signaling pathway. The therapeutic potential of MAN@DHQ in ASD treatment represents a paradigm-shifting advancement in autism pharmacotherapy and offers promise for clinical interventions for ASD patients.
- 18 December 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (1) , 157-173
Therapeutic Efficacy of a Synthetic Brain-Targeted H2S Donor Cross-Linked Nanomicelle in Autism Spectrum Disorder Rats through Aerobic Glycolysis
Autism spectrum disorder (ASD) is characterized by cognitive inflexibility and social deficits, with a notably limited range of brain-targeted medications, particularly in the field of nanomedicine. Herein, we introduce the brain-targeted H2S donor cross-linked nanomicelle, named mannose-PEG600-lipoic acid (Man-LA). Man-LA demonstrates enhanced stability and precise brain delivery by interacting with glucose transporter 1 (GLUT1) in astrocytes, facilitating a gradual release of H2S that is modulated by glutathione (GSH). In vivo, studies suggest that Man-LA alleviates symptoms of ASD, correlating with increased expression of aerobic glycolysis enzymes, elevated lactate production, and higher H2S levels, while preventing damage to hippocampal neurons. In vitro, Man-LA tightly binds to aldehyde dehydrogenase family 3 member B1 (Aldh3b1) in astrocytes, upregulating its expression. This interaction promotes aerobic glycolysis and enhances lactate production. These findings suggest a connection between ASD deficits and the dysregulation of astrocytic aerobic glycolysis, underscoring the role of H2S. Identifying the Aldh3b1 gene within aerobic glycolysis pathways provides a promising target for ASD treatment.
- 18 December 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (1) , 157-173
Therapeutic Efficacy of a Synthetic Brain-Targeted H2S Donor Cross-Linked Nanomicelle in Autism Spectrum Disorder Rats through Aerobic Glycolysis
Autism spectrum disorder (ASD) is characterized by cognitive inflexibility and social deficits, with a notably limited range of brain-targeted medications, particularly in the field of nanomedicine. Herein, we introduce the brain-targeted H2S donor cross-linked nanomicelle, named mannose-PEG600-lipoic acid (Man-LA). Man-LA demonstrates enhanced stability and precise brain delivery by interacting with glucose transporter 1 (GLUT1) in astrocytes, facilitating a gradual release of H2S that is modulated by glutathione (GSH). In vivo, studies suggest that Man-LA alleviates symptoms of ASD, correlating with increased expression of aerobic glycolysis enzymes, elevated lactate production, and higher H2S levels, while preventing damage to hippocampal neurons. In vitro, Man-LA tightly binds to aldehyde dehydrogenase family 3 member B1 (Aldh3b1) in astrocytes, upregulating its expression. This interaction promotes aerobic glycolysis and enhances lactate production. These findings suggest a connection between ASD deficits and the dysregulation of astrocytic aerobic glycolysis, underscoring the role of H2S. Identifying the Aldh3b1 gene within aerobic glycolysis pathways provides a promising target for ASD treatment.
- 22 April 2023
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 47 (20) , 9833-9841
Detection of H2S using a novel fluorescent nanoprobe in plasma and tissue samples from ASD patients and model mice
A novel fluorescent nanoprobe was prepared to measure H2S in plasma and tissue samples from ASD patients and model mice.
- 22 April 2023
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 47 (20) , 9833-9841
Detection of H2S using a novel fluorescent nanoprobe in plasma and tissue samples from ASD patients and model mice
A novel fluorescent nanoprobe was prepared to measure H2S in plasma and tissue samples from ASD patients and model mice.
- Open Access
- 29 December 2022
- Published by Taylor & Francis in Drug Delivery
- Vol. 30 (1) , 2162160
Nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy based on NADPH depletion
Hepatocellular carcinoma (HCC) is a malignant tumor leading cancer-associated high mortality worldwide. Unfortunately, the most commonly used drug therapeutics not only lack of target ability and efficiency, but also exhibit severe systemic toxicity to normal tissues. Thus, effective and targeted nanodrug of HCC therapy is emerging as a more important issue. Here, we design and develop the novel nanomicelles, namely Mannose-polyethylene glycol 600-Nitroimidazole (Man-NIT). This micelle compound with high purity comprise two parts, which can self-assemble into nanoscale micelle. The outer shell is selected mannose as hydrophilic moiety, while the inner core is nitroimidazole as hydrophobic moiety. In the cell experiment, Man-NIT was more cellular uptake by HCCLM3 cells due to the mannose modification. Mannose as a kind of glucose transporter 1 (GLUT1) substrate, can specifically recognize and bind to over-expressed GLUT1 on carcinoma cytomembrane. The nitroimidazole moiety of Man-NIT was reduced by the over-expressed nitroreductase with reduced nicotinamide adenine dinucleotide phosphate (NADPH) as the cofactor, resulting in transient deletion of NADPH and glutathione (GSH). The increase of reactive oxygen species (ROS) in HCCLM3 cells disturbed the balance of redox, and finally caused the death of tumor cells. Additional in vivo experiment was conducted using twenty-four male BALB/c nude mice to build the tumor model. The results showed that nanomicelles were accumulated in the liver of mice. The tumor size and pathological features were obviously improved after nanomicelles treatment. It indicates that namomicelles have a tumor inhibition effect, especially Man-NIT, which may be a potential nanodrug of chemotherapeutics for HCC therapy.
- 29 December 2022
- Published by Taylor & Francis in Drug Delivery
- Vol. 30 (1) , 2162160
Open AccessNanomicelles for GLUT1-targeting hepatocellular carcinoma therapy based on NADPH depletion
Hepatocellular carcinoma (HCC) is a malignant tumor leading cancer-associated high mortality worldwide. Unfortunately, the most commonly used drug therapeutics not only lack of target ability and efficiency, but also exhibit severe systemic toxicity to normal tissues. Thus, effective and targeted nanodrug of HCC therapy is emerging as a more important issue. Here, we design and develop the novel nanomicelles, namely Mannose-polyethylene glycol 600-Nitroimidazole (Man-NIT). This micelle compound with high purity comprise two parts, which can self-assemble into nanoscale micelle. The outer shell is selected mannose as hydrophilic moiety, while the inner core is nitroimidazole as hydrophobic moiety. In the cell experiment, Man-NIT was more cellular uptake by HCCLM3 cells due to the mannose modification. Mannose as a kind of glucose transporter 1 (GLUT1) substrate, can specifically recognize and bind to over-expressed GLUT1 on carcinoma cytomembrane. The nitroimidazole moiety of Man-NIT was reduced by the over-expressed nitroreductase with reduced nicotinamide adenine dinucleotide phosphate (NADPH) as the cofactor, resulting in transient deletion of NADPH and glutathione (GSH). The increase of reactive oxygen species (ROS) in HCCLM3 cells disturbed the balance of redox, and finally caused the death of tumor cells. Additional in vivo experiment was conducted using twenty-four male BALB/c nude mice to build the tumor model. The results showed that nanomicelles were accumulated in the liver of mice. The tumor size and pathological features were obviously improved after nanomicelles treatment. It indicates that namomicelles have a tumor inhibition effect, especially Man-NIT, which may be a potential nanodrug of chemotherapeutics for HCC therapy.
- Open Access
- 1 January 2021
- Published by Taylor & Francis in Drug Delivery
- Vol. 28 (1) , 1903-1914
Design and evaluation of glutathione responsive glycosylated camptothecin nanosupramolecular prodrug
A novel tumor-targeted glutathione responsive Glycosylated-Camptothecin nanosupramolecular prodrug (CPT-GL NSp) was designed and fabricated via a disulfide bond. The effects of glycoligand with different polarities on solubility, self-assembly, stability, cellular uptake, and glutathione responsive cleaving were explored, and an optimal glycosylated ligand was selected for nanosupramolecular prodrug. It has been found that CPT-GL NSp exhibited higher drug loading than traditional nanoparticles. Among of which maltose modified NSp had the strongest anti-tumor effects than that of glucose and maltotriose. CPT-SS-Maltose had a similar anti-tumor ability to Irinotecan (IR), but the superior performance in solubility, hemolysis, and uptake of HepG2 cells.
- 1 January 2021
- Published by Taylor & Francis in Drug Delivery
- Vol. 28 (1) , 1903-1914
Open AccessDesign and evaluation of glutathione responsive glycosylated camptothecin nanosupramolecular prodrug
A novel tumor-targeted glutathione responsive Glycosylated-Camptothecin nanosupramolecular prodrug (CPT-GL NSp) was designed and fabricated via a disulfide bond. The effects of glycoligand with different polarities on solubility, self-assembly, stability, cellular uptake, and glutathione responsive cleaving were explored, and an optimal glycosylated ligand was selected for nanosupramolecular prodrug. It has been found that CPT-GL NSp exhibited higher drug loading than traditional nanoparticles. Among of which maltose modified NSp had the strongest anti-tumor effects than that of glucose and maltotriose. CPT-SS-Maltose had a similar anti-tumor ability to Irinotecan (IR), but the superior performance in solubility, hemolysis, and uptake of HepG2 cells.
- 1 November 2020
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 156, 143-154
Kidney-targeted astaxanthin natural antioxidant nanosystem for diabetic nephropathy therapy
- 1 November 2020
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 156, 143-154
Kidney-targeted astaxanthin natural antioxidant nanosystem for diabetic nephropathy therapy